Αναζήτηση
Αποτελέσματα 41-50 από 105
Helicobacter pylori and autoimmune disease: Cause or bystander
(2014)
Helicobacter pylori (H. pylori) is the main cause of chronic gastritis and a major risk factor for gastric cancer. This pathogen has also been considered a potential trigger of gastric autoimmunity, and in particular of ...
PBC triggers in water reservoirs, coal mining areas and waste disposal sites: From Newcastle to New York
(2010)
Various environmental factors have been proposed as triggers of primary biliary cirrhosis (PBC), a progressive autoimmune cholestatic liver disease which is characterised by the destruction of the small intrahepatic bile ...
Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production
(2005)
We have recently reported differences in the hematopoiesis between autoimmune hepatitis type I (AIH-1) and primary biliary cirrhosis (PBC). In view of the notion that cytokines are regulators of hematopoiesis, we investigated ...
Oxidative stress and antioxidant status in patients with autoimmune liver diseases
(2015)
Objective: To estimate oxidative stress and antioxidant components during different stages of autoimmune liver diseases and assess their possible implication on disease progression. Methods: We determined several markers ...
Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic
(2005)
The serological hallmark of primary biliary cirrhosis (PBC) is the presence of pyruvate dehydrogenase complex E2 subunit (PDC-E2) antimitochondrial antibodies (AMAs). Anti-PDC-E2 antibodies cross-react specifically with ...
Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection
(2003)
Background and aims. Recurrent urinary tract infections (rUTI) have been suggested to be involved in the induction of anti-mitochondrial antibodies (AMA), the serological hallmark of primary biliary cirrhosis (PBC), in ...
Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients
(2011)
Background & Aims: Standard therapy for autoimmune hepatitis (AIH) is corticosteroids with or without azathioprine. However, 20% of patients do not respond or are intolerant to conventional treatment. Therefore, we evaluated ...
Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients
(2011)
Background & Aims: Standard therapy for autoimmune hepatitis (AIH) is corticosteroids with or without azathioprine. However, 20% of patients do not respond or are intolerant to conventional treatment. Therefore, we evaluated ...